24 Hours of Stem Cells
Live keynote presentations
Join us live on November 6 to listen to presentations from thought leaders in stem cell research.

Register now

Development of chemically defined cell culture for human pluripotent stem cells.
Guokai Chen, PhD
Director of iPSC Core Facility, Associate Professor, Faculty of Health Sciences
University of Macau, China

Details >
Induced pluripotent stem cells: time for standards.
Mathilde Girard, PhD
Institute for Stem cell Therapy and Exploration of Monogenic diseases (I-Stem)
Evry, France

Details >
Utility of gene expression signatures for the characterization of cellular identity.
Alexander Meissner, PhD
Senior Associate Member, Broad Institute of MIT and Harvard, Associate Professor Department of Stem Cell and Regenerative Biology, Principal Faculty, Harvard Stem Cell Institute
Cambridge, MA, United States

Details >

On-demand presentations
Pre-recorded for viewing on your schedule.

Register now

Pharmacological modulation of cell fates / 细胞命运的药理学调节机制
Yu Wang, Ph.D
Professor, Institute of Zoology, Chinese Academy of Sciences
Beijing, China

Details >
Transcriptome profiling and stem cell-based therapies / 转录组分型和干细胞治疗
Yi E. Sun, Ph.D.
Director of Stem Cell Research Center, School of Medicine, Tongji University
Shanghai, China

Details >
Developing a human embryonic stem cell based therapy for multiple sclerosis
Dr. Ren-He Xu
Professor, Faculty of Health Sciences, University of Macau
Taipa, Macau

Details >
Personalized Disease Model in Dish - Starting with Parkinson's Disease /从帕金森疾病开始浅谈培养皿中的个性化疾病模型
Jing He, Ph.D / Bo Peng, Ph.D
Life Sciences Solutions Group, Thermo Fisher Scientific

Details >
Growth factor signaling regulates breast cancer stem cells
Noriko Gotoh, MD, PhD
Professor, Division of Cancer Cell Biology
Cancer Research Institute, Kanazawa University, Japan

Details >
The future of pluripotent stem cell banking
Loh Yuin-Han Jonathan, PhD
Principal Investigator, A*STAR Institute of Molecular and Cell Biology

Details >
Cellular Immune Therapy for virus-associated human malignancies and post-transplant infectious complications
Rajiv Khanna, PhD
QIMR Centre for Immunotherapy and Vaccine Development
QIMR Berghofer Medical Research Institute
Brisbane, Queensland, Australia

Details >
Mechanisms of reprogramming: applying lessons from mouse models to improve the efficiency of an iPSC core facility
Laurent David, PhD
Associate professor at the Medical School of Nantes, Head of the iPSC core facility of Nantes
Nantes, France

Details >
Pluripotency factors and cell lineage specification
Michel Pucéat, PhD
Team physiopathology of cardiac development, Aix-Marseille University, Medical School La Timone
Marseille, France

Details >
Reversibility of the cellular aging physiology through an iPSC state : a new paradigm for human cell rejuvenation
Jean-Marc Lemaitre, PhD
Deputy Director of the Institute of Regenerative Medicine and Biotherapies
Director of INSERM Laboratory Genome and Stem Cell Plasticity in Development and Aging
Director of the Stem Cell Core Facility SAFE-iPSC
Saint Eloi Hospital, CHRU Montpellier
Montpellier, France

Details >
Chromatin modifiers in reprogramming
Tamer T. Önder, PhD
Assistant Professor, Koç University, School of Medicine
Istanbul, Turkey

Details >
Scalable Production of Human Stem/Progenitor Cells in Bioreactor Systems
Cláudia Lobato da Silva, PhD
Stem Cell Bioengineering and Regenerative Medicine Laboratory, Instituto Superior Técnico, Universidade de Lisboa

Details >
Knock-in gene correction in Pyruvate Kinase Deficiency patient-derived iPSC, the most common metabolic erythroid disease
José Carlos Segovia, Ph.D.
Differentiation and Cytometry Unit. Division of Hematopoietic Innovative Therapies, CIEMAT/CIBERER, Madrid, Spain.
Instituto de Investigacion Sanitaria Fundacion Jimenez Diaz (IIS-FJD, UAM), Madrid, Spain

Details >
Using iPS cell technology to model human neurodegenerative diseases
Angel Raya, MD, PhD
ICREA Research Professor, Institute for Bioengineering of Catalonia (IBEC); Director, Center for Regenerative Medicine in Barcelona (CMRB)
Barcelona, Spain

Details >
SCL/TAL1-mediated transcriptional network enhances megakaryocytic specification of human embryonic stem cells
Pedro J. Real PhD
Genomic Oncology Department
GENYO - Centre for Genomics and Oncological Research: Pfizer-University of Granada-Andalusian Regional Government. PTS Granada
Granada, Spain

Details >
iPSCs for modeling disease in Africa
Janine Scholefield, PhD
Post-doctoral Fellow, Gene Expression & Biophysics Group, Synthetic Biology ERA
Council for Scientific and Industrial Research
South Africa

Details >
Use of pluripotent stem cells to model premature aging syndromes
Xavier Nissan, PhD
CECS, I-STEM, AFM, Institute for Stem cell Therapy and Exploration of Monogenic diseases
Evry, Cedex, France

Details >
Deriving functional hepatocytes from pluripotent stem cells
David Hay, PhD
MRC Centre for Regenerative Medicine
Edinburgh, United Kingdom

Details >
Culture adaptation of pluripotent stem cells: an in vitro model for oncogenesis
Ivana Barbaric, PhD
Lecturer, Centre for Stem Cell Biology, Department of Biomedical Science, University of Sheffield
Western Bank, Sheffield, United Kingdom

Details >
The challenges and possible solutions for transferring cell therapy from the bench to the industry, while assuring high quality and manufacturing efficiency
Ohad Karnieli, PhD, MBA
Vice President Technology & Manufacturing
Pluristem Therapeutics, Inc.
Haifa, Israel

Details >
Reprogramming cells to study mental disorders
Stevens Rehen, PhD
Institute of Biomedical Sciences, Federal University of Rio de Janeiro and D'Or Institute for Research and Education
Rio de Janeiro, Brazil

Details >
Pluripotent stem cells to model human brain development
Christopher Fasano, PhD
Principal Investigator
Neural Stem Cell Institute
Rensselaer, NY, United States

Details >
Reprogramming somatic cells using the Sendai virus technology
Laurence Daheron, PhD
Harvard Stem Cell Institute
Cambridge, MA, United States

Details >
Developing a human ES cell–derived dopamine neuron source for cell therapy in Parkinson's disease - from academic to translational research
Stefan Irion, MD
Program Manager, NYSTEM Consortia; Memorial Sloan Kettering Cancer Center
New York, NY, United States

Details >
Molecular engineering of biomaterial platforms for scalable stem cell manufacturing
David V. Schaffer, PhD
Professor of Chemical and Biomolecular Engineering, Bioengineering, and Neuroscience
Director of the Berkeley Stem Cell Center
University of California at Berkeley
Berkeley, CA, United States

Details >
Stage-specific grafting of hESC-derived midbrain dopamine neurons
Yosif Martin Ganat, PhD
Postdoctoral Fellow, Memorial Sloan Kettering Cancer Center
New York, NY, United States

Details >
Hematopoietic disease modeling using induced pluripotent stem cells
Deborah L. French, PhD
Director, Stem Cell Core Facility
The Children's Hospital of Philadelphia
Philadelphia, PA, United States

Details >
iPSC reprogramming from human blood using Sendai virus–mediated gene transfer
Wenli Yang, PhD
Director, iPS Cell Core
Institute for Regenerative Medicine
University of Pennsylvania
Philadelphia, PA, United States

Details >
Developing autologous cell therapy for macular degeneration using iPS cell derived RPE tissue: A model for public-private partnership
Kapil Bharti, PhD
Earl Stadtman Tenure-Track Investigator
Head Unit on Ocular and Stem Cell Translational Research
National Eye Institute, National Institutes of Health
Bethesda, MD, United States

Details >
Differentiate pluripotent stem cells to contracting cardiomyocytes in 3 easy steps
Alex Hannay
Product Manager, Cell Biology
Life Sciences Solutions
Thermo Fisher Scientific

Details >
Rapid induction of neural stem cells without the need for EB formation
Alex Hannay
Product Manager, Cell Biology
Life Sciences Solutions
Thermo Fisher Scientific

Details >
Considerations for the culture of pluripotent stem cells
Jennifer J. Crean
Senior Manager, Product Management
Biosciences Division, Life Sciences Solutions Group
Thermo Fisher Scientific

Details >
Quantify trilineage differentiation potential using a gene expression profile for your iPS lines
Deborah Tieberg
Product Manager, Life Technologies Brand
Biosciences Division
Thermo Fisher Scientific

Details >
Eliminate serum to gain control of T cell research—new T cell–defined serum replacement
Sandy Kuligowski
Senior Manager, Product Development, Adult Stem Cell and Cell Therapy Products
Life Technologies Brand, Life Science Solutions Group
Thermo Fisher Scientific

Details >
Considerations for creating a disease model for Parkinson's disease using stem cells
Kurt W. Vogel, PhD
Associate Director, External R&D
Cell Biology, Life Sciences Solutions
Thermo Fisher Scientific

Details >
Antibody-based tools and protocols for characterization of pluripotent stem cells
Nirupama (Rupa) Shevde, PhD
Senior Stem Cell Scientist and Global Training Manager
Cell Biology, Life Sciences Solutions
Thermo Fisher Scientific

Details >
Hands-free stem cell research: services to save you time
Carolyn Pettersson
Senior Manager, Discovery Services
Biosciences, Life Sciences Solutions
Thermo Fisher Scientific

Details >
Efficient cell specific differentiation systems for iPSC
Mohan C. Vemuri, Ph.D
Director, Cell Biology
Thermo Fisher Scientific

Details >
Trends and Considerations for Cell Therapy Development
Eric J. Roos
Strategic Alliances Leader, Cell Therapy
Cell Biology, Life Science Solutions
Thermo Fisher Scientific

Details >